Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronicobstructivepulmonarydisease (COPD) and an eosinophilic phenotype ...
in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you